{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:58:08Z","timestamp":1777723088214,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.semnephrol.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T18:26:53Z","timestamp":1525890413000},"page":"267-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["HIF Activation Against CVD in CKD: Novel Treatment Opportunities"],"prefix":"10.1016","volume":"38","author":[{"given":"Tetsuhiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.02.006_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"issue":"Suppl 8","key":"10.1016\/j.semnephrol.2018.02.006_bib3","first-page":"viii7","article-title":"The cardio-renal anaemia syndrome: does it exist?","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib5","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib6","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1093\/emboj\/cdg392","article-title":"HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia","volume":"22","author":"Berra","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib7","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1096\/fj.04-1640fje","article-title":"Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells","volume":"18","author":"Warnecke","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1681\/ASN.2006060639","article-title":"Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney","volume":"18","author":"Kojima","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib10","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2007-10-117812","article-title":"Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure","volume":"111","author":"Minamishima","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMoa073123","article-title":"A gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","article-title":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","volume":"92","author":"Sugahara","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib16","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib17","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib18","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib19","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jacc.2005.08.045","article-title":"Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse","volume":"46","author":"Kido","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.107.758516","article-title":"Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning","volume":"118","author":"Eckle","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib21","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.1074\/jbc.M110.186809","article-title":"Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury","volume":"286","author":"Holscher","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib22","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1074\/jbc.M109.084855","article-title":"Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury","volume":"285","author":"Hyvarinen","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib23","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00424-014-1667-z","article-title":"Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult","volume":"467","author":"Vogler","year":"2015","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.109.922427","article-title":"Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy","volume":"122","author":"Moslehi","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib25","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1128\/MCB.01580-07","article-title":"Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein","volume":"28","author":"Lei","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2009.05.005","article-title":"Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy","volume":"9","author":"Krishnan","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05602","article-title":"p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload","volume":"446","author":"Sano","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib28","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1073\/pnas.1202081109","article-title":"Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-beta signaling","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib30","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib31","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1084\/jem.20070885","article-title":"The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions","volume":"204","author":"Nahrendorf","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib32","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1084\/jem.182.6.1683","article-title":"A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter","volume":"182","author":"Melillo","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib33","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1038\/ncomms11635","article-title":"HIF-1alpha-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity","volume":"7","author":"Semba","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0092-8674(03)00154-5","article-title":"HIF-1alpha is essential for myeloid cell-mediated inflammation","volume":"112","author":"Cramer","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib35","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI90848","article-title":"Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses","volume":"127","author":"Sadiku","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib36","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000468952","article-title":"Fibroblast growth factor 23: mineral metabolism and beyond","volume":"190","author":"Grabner","year":"2017","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib38","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib41","doi-asserted-by":"crossref","first-page":"e0186979","DOI":"10.1371\/journal.pone.0186979","article-title":"FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase","volume":"12","author":"Flamme","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib42","doi-asserted-by":"crossref","first-page":"e0176984","DOI":"10.1371\/journal.pone.0176984","article-title":"High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients","volume":"12","author":"Honda","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/01.CIR.28.5.915","article-title":"The terminal portion of the pulmonary arterial tree in people native to high altitudes","volume":"28","author":"Arias-Stella","year":"1963","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2008-04-153718","article-title":"Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation","volume":"112","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14814\/phy2.13224","article-title":"Cardiopulmonary phenotype associated with human PHD2 mutation","volume":"5","author":"Talbot","year":"2017","journal-title":"Physiol Rep"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib46","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1371\/journal.pmed.0030290","article-title":"Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology","volume":"3","author":"Smith","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ng.3067","article-title":"A genetic mechanism for Tibetan high-altitude adaptation","volume":"46","author":"Lorenzo","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1152\/japplphysiol.00535.2013","article-title":"Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia","volume":"116","author":"Petousi","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib49","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI15496","article-title":"Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia","volume":"111","author":"Brusselmans","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib50","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1073\/pnas.1602978113","article-title":"HIF2alpha-arginase axis is essential for the development of pulmonary hypertension","volume":"113","author":"Cowburn","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib51","doi-asserted-by":"crossref","first-page":"17134","DOI":"10.1074\/jbc.M112.444059","article-title":"Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation","volume":"288","author":"Tan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/j.ajkd.2012.07.029","article-title":"Pulmonary hypertension in CKD","volume":"61","author":"Bolignano","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib54","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2007.12.025","article-title":"Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis","volume":"51","author":"Sluimer","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib55","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/ATVBAHA.115.306171","article-title":"Deficiency of HIF1alpha in antigen-presenting cells aggravates atherosclerosis and type 1 T-helper cell responses in mice","volume":"35","author":"Chaudhari","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib56","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1161\/ATVBAHA.116.307830","article-title":"Hypoxia-inducible factor-1alpha expression in macrophages promotes development of atherosclerosis","volume":"36","author":"Aarup","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/bj3340009","article-title":"Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor","volume":"334","author":"Yoshida","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.04.034","article-title":"Hypoxia enhances lipid uptake in macrophages: role of the scavenger receptors Lox1, SRA, and CD36","volume":"229","author":"Crucet","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(02)00236-X","article-title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis","volume":"95","author":"Chen","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib60","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/01.ATV.0000133488.56221.4a","article-title":"Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure","volume":"24","author":"Choi","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib61","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1681\/ASN.2009010061","article-title":"The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD","volume":"20","author":"Di Marco","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib62","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.kint.2016.09.028","article-title":"Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease","volume":"91","author":"Schellinger","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib64","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib67","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db14-0472","article-title":"HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction","volume":"63","author":"Rahtu-Korpela","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib68","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.113.001742","article-title":"Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance","volume":"127","author":"Matsuura","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib69","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib70","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1093\/eurheartj\/ehw156","article-title":"Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia","volume":"37","author":"Marsch","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib71","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib72","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1523-1755.2001.060002741.x","article-title":"Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency","volume":"60","author":"Locatelli","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib74","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib75","doi-asserted-by":"crossref","first-page":"17570","DOI":"10.1073\/pnas.1306942110","article-title":"HIF isoforms in the skin differentially regulate systemic arterial pressure","volume":"110","author":"Cowburn","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib76","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.1881410","article-title":"Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis","volume":"24","author":"Takeda","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib77","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1128\/MCB.02041-07","article-title":"Abnormal sympathoadrenal development and systemic hypotension in PHD3-\/- mice","volume":"28","author":"Bishop","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib78","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1073\/pnas.1100064108","article-title":"Hypoxia-inducible factor 2alpha (HIF-2alpha) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension","volume":"108","author":"Peng","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib79","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/HYPERTENSIONAHA.109.145896","article-title":"Hypoxia-inducible factor prolyl-hydroxylase 2 senses high-salt intake to increase hypoxia inducible factor 1alpha levels in the renal medulla","volume":"55","author":"Wang","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib80","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bbadis.2012.02.002","article-title":"Overexpression of HIF-1alpha transgene in the renal medulla attenuated salt sensitive hypertension in Dahl S rats","volume":"1822","author":"Zhu","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ajh\/hpt207","article-title":"Silencing of HIF prolyl-hydroxylase 2 gene in the renal medulla attenuates salt-sensitive hypertension in Dahl S rats","volume":"27","author":"Zhu","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib82","doi-asserted-by":"crossref","first-page":"e0157282","DOI":"10.1371\/journal.pone.0157282","article-title":"Correction: adipose tissue-derived mesenchymal stem cells in long-term dialysis patients display downregulation of PCAF expression and poor angiogenesis activation","volume":"11","author":"Yamanaka","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.02.006_bib83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ki.2015.21","article-title":"Inflammation and hypoxia linked to renal injury by CCAAT\/enhancer-binding protein delta","volume":"88","author":"Yamaguchi","year":"2015","journal-title":"Kidney Int"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T17:55:23Z","timestamp":1534874123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518300275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0270929518300275"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.02.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIF Activation Against CVD in CKD: Novel Treatment Opportunities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}